BioDuro-Sundia and X-Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs


In order to assist more creative pharmaceutical companies quickly discover small molecule drugs, BioDuro-Sundia, an industry-leading drug discovery, development, and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China. To help customers greatly speed up the discovery of hits and broaden their target area, X-Chem will make use of its potent DEL technology platform and big collection of innovative, diverse lead- and drug-like small molecule compounds. Customers can receive top-tier discovery tools and support, including hit identification and optimization, evaluation of lead and candidate compounds, and swift progression to preclinical development, when combined with BioDuro-one-stop Sundia’s drug discovery platform.

X-Chem is a leader in DEL technology, and its libraries hold more than 250 billion tiny compounds. With over 300 separate chemical series and more than a thousand validated hit compounds, X-Chem has licenced more than 100 research projects to businesses in the US, Europe, and Japan. To help customers qualify proteins and verify that their purity, concentration, and degree of aggregation satisfy the criteria for compound library screening to maximise the likelihood of hit identification, BioDuro-Sundia will make use of its robust protein screening technology.

“We are very pleased to collaborate with BioDuro-Sundia in China to explore more new and challenging, valuable therapeutic targets”, “We believe that X-Chem’ s DEL platform technology, in strong association with BioDuro-Sundia’s one-stop new drug discovery development platform, can deliver promising drug leads and will bring higher value returns to our biopharma clients.”

X-Chem s  CBO, Steffen Helmling

BioDuro-Sundia is an integrated CRDMO that offers services for drug development, manufacture, and discovery. The organisation has more than 18 years of experience in discovery chemical services, and as a leader in drug development, it has successfully completed thousands of projects to date.

“We look forward to working with X-Chem to help our customers discover more novel small molecule leads through the application of DNA Encoded Compound Library (DEL)”, “This collaboration will provide a cutting-edge platform for hit identification in early drug discovery and further expand BioDuro-Sundia’s one-stop new drug discovery and development capabilities. It will also empower innovative Chinese pharmaceutical companies with a more efficient drug discovery mechanism. We believe that through our collaboration with X-Chem scientists, new drug candidates will continue to be discovered and advanced, eventually moving towards the clinic and benefiting patients.”

Dr. Xiang Li, Drug Discovery President of BioDuro-Sundia

Next Post

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that give hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc., announced today that the two companies have entered into a binding agreement (SCD). The acquisition strengthens the […]